IL-15 was found to significantly augment the magnitude and duration of the anti-tumor response in the EL4-hCD20 syngeneic model treated with Rituximab and the ALT MET-1 xenograft model treated with Alemtuzumab (50). The gene discussed is IL15; the disease is neoplasm.